These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [Ru III/II Cl6-n(Azole)n]z(n = 3, 4, 6) complexes. Reisner E; Arion VB; Eichinger A; Kandler N; Giester G; Pombeiro AJ; Keppler BK Inorg Chem; 2005 Sep; 44(19):6704-16. PubMed ID: 16156629 [TBL] [Abstract][Full Text] [Related]
6. Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids. Filak LK; Kalinowski DS; Bauer TJ; Richardson DR; Arion VB Inorg Chem; 2014 Jul; 53(13):6934-43. PubMed ID: 24927493 [TBL] [Abstract][Full Text] [Related]
9. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity. Bratsos I; Serli B; Zangrando E; Katsaros N; Alessio E Inorg Chem; 2007 Feb; 46(3):975-92. PubMed ID: 17257042 [TBL] [Abstract][Full Text] [Related]
12. Elucidation of Structure-Activity Relationships in Indolobenzazepine-Derived Ligands and Their Copper(II) Complexes: the Role of Key Structural Components and Insight into the Mechanism of Action. Kuznetcova I; Bacher F; Alfadul SM; Tham MJR; Ang WH; Babak MV; Rapta P; Arion VB Inorg Chem; 2022 Jul; 61(26):10167-10181. PubMed ID: 35713376 [TBL] [Abstract][Full Text] [Related]
13. En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2]. Büchel GE; Stepanenko IN; Hejl M; Jakupec MA; Keppler BK; Arion VB Inorg Chem; 2011 Aug; 50(16):7690-7. PubMed ID: 21739939 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization and DNA binding studies of two mixed ligand complexes of ruthenium(II). Lawrence D; Vaidyanathan VG; Nair BU J Inorg Biochem; 2006 Jul; 100(7):1244-51. PubMed ID: 16554091 [TBL] [Abstract][Full Text] [Related]
15. Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. Mura P; Camalli M; Casini A; Gabbiani C; Messori L J Inorg Biochem; 2010 Feb; 104(2):111-7. PubMed ID: 19939460 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of water-soluble, heteronuclear ruthenium(III)/ferrocene complexes and their interactions with biomolecules. Anderson CM; Jain SS; Silber L; Chen K; Guha S; Zhang W; McLaughlin EC; Hu Y; Tanski JM J Inorg Biochem; 2015 Apr; 145():41-50. PubMed ID: 25621836 [TBL] [Abstract][Full Text] [Related]
18. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates. Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, in vitro antitumor activity, DNA-binding properties and electronic structure (DFT) of the new complex cis-(Cl,Cl)[RuIICl2(NO+)(terpy)]Cl. Karidi K; Garoufis A; Tsipis A; Hadjiliadis N; den Dulk H; Reedijk J Dalton Trans; 2005 Apr; (7):1176-87. PubMed ID: 15782252 [TBL] [Abstract][Full Text] [Related]
20. Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. Schmid WF; John RO; Mühlgassner G; Heffeter P; Jakupec MA; Galanski MS; Berger W; Arion VB; Keppler BK J Med Chem; 2007 Dec; 50(25):6343-55. PubMed ID: 17997519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]